NLRP3 and colitis: Based on this background, the present study was designed to investigate how the direct blockade of NLRP3 with INF39 in experimental colitis compares, in terms of efficacy, with other drugs acting downstream (caspase-1 inhibition or IL-1β receptor blockade) on NLRP3 signaling.